Your browser is no longer supported. Please, upgrade your browser.
Settings
ADMS Adamas Pharmaceuticals, Inc. daily Stock Chart
ADMS [NASD]
Adamas Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.88 Insider Own1.00% Shs Outstand27.98M Perf Week-0.93%
Market Cap178.23M Forward P/E- EPS next Y-2.52 Insider Trans-3.23% Shs Float26.87M Perf Month-16.84%
Income-131.00M PEG- EPS next Q-1.15 Inst Own- Short Float24.79% Perf Quarter-26.53%
Sales34.00M P/S5.24 EPS this Y-22.80% Inst Trans5.05% Short Ratio11.51 Perf Half Y-65.08%
Book/sh3.29 P/B1.94 EPS next Y41.10% ROA-49.10% Target Price28.78 Perf Year-77.32%
Cash/sh7.54 P/C0.85 EPS next 5Y17.90% ROE-101.50% 52W Range6.15 - 32.90 Perf YTD-25.41%
Dividend- P/FCF- EPS past 5Y-29.00% ROI-55.00% 52W High-80.64% Beta1.38
Dividend %- Quick Ratio9.20 Sales past 5Y-13.70% Gross Margin98.10% 52W Low3.58% ATR0.28
Employees159 Current Ratio9.40 Sales Q/Q2244.20% Oper. Margin- RSI (14)28.58 Volatility4.15% 4.05%
OptionableYes Debt/Eq1.31 EPS Q/Q17.10% Profit Margin- Rel Volume0.36 Prev Close6.28
ShortableYes LT Debt/Eq1.31 EarningsJun 03 AMC Payout- Avg Volume578.76K Price6.37
Recom2.30 SMA20-6.56% SMA50-23.28% SMA200-56.01% Volume208,601 Change1.43%
Mar-05-19Downgrade Mizuho Neutral → Underperform $11 → $5
Nov-05-18Downgrade Mizuho Buy → Neutral
Oct-05-18Downgrade BofA/Merrill Buy → Neutral
Jul-16-18Initiated H.C. Wainwright Buy $45
Apr-04-18Initiated Leerink Partners Outperform $31
Mar-27-18Initiated BofA/Merrill Buy $39
Nov-29-17Initiated Northland Capital Outperform $70
Nov-08-17Reiterated Noble Financial Buy $33 → $48
Oct-30-17Initiated Evercore ISI Outperform $85
Sep-29-17Resumed Noble Financial Buy $33
Sep-19-17Reiterated Mizuho Buy $26 → $48
Aug-25-17Reiterated JMP Securities Mkt Outperform $29 → $33
Sep-08-16Reiterated Mizuho Buy $22 → $26
Jun-17-16Initiated Noble Financial Buy $25
Jun-16-16Upgrade Mizuho Neutral → Buy $22
May-12-16Reiterated Mizuho Neutral $17 → $16
Apr-28-16Reiterated Mizuho Neutral $14 → $17
Apr-01-16Initiated JMP Securities Mkt Outperform
Jan-19-16Initiated Mizuho Neutral $26
Dec-24-15Reiterated Credit Suisse Outperform $35 → $37
Apr-22-19 03:00PM  New Electric Vehicles Contain Much More Lithium Oilprice.com
02:46PM  Before You Buy Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), Consider Its Volatility Simply Wall St.
Mar-12-19 04:05PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Mar-08-19 02:49PM  Edited Transcript of ADMS earnings conference call or presentation 4-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-05-19 12:40PM  Why Adamas Pharmaceuticals Shares Are Crashing Today Motley Fool -32.84%
07:24AM  The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings Benzinga
Mar-04-19 09:34PM  Adamas Pharmaceuticals Inc (ADMS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:35PM  Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018 GlobeNewswire
Feb-26-19 09:41AM  Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4? Zacks
Feb-21-19 10:31AM  Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Feb-20-19 04:50PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire +5.24%
04:49PM  Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019 GlobeNewswire
09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
08:18AM  Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings? Zacks
Feb-18-19 08:18AM  AptarGroup (ATR) to Report Q4 Earnings: What's in Store? Zacks
07:25AM  Milacron (MCRN) to Report Q4 Earnings: What's in Store? Zacks
Feb-12-19 02:26PM  Should You Be Worried About Insider Transactions At Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? Simply Wall St.
Feb-08-19 06:49PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Feb-07-19 10:34AM  Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings? Zacks
08:15AM  Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-01-19 11:30AM  LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index ACCESSWIRE
Jan-10-19 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
10:49AM  Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December Motley Fool
Jan-06-19 11:38AM  Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI Sales Results and Outlines Key Priorities for 2019 GlobeNewswire
Dec-19-18 07:46AM  The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas Benzinga
Dec-18-18 04:30PM  Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI GlobeNewswire -7.74%
Dec-17-18 09:43PM  Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy? Insider Monkey -5.59%
Dec-11-18 03:29PM  Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November Motley Fool
Nov-15-18 01:47PM  Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 01:49PM  Adamas to Present at Three November Investor Conferences GlobeNewswire -8.46%
Nov-08-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX New Research Emphasizes Economic Growth GlobeNewswire
Nov-02-18 11:37AM  The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today Motley Fool -29.94%
Nov-01-18 05:52PM  Adamas: 3Q Earnings Snapshot Associated Press
04:01PM  Adamas Reports Third Quarter 2018 Financial Results GlobeNewswire
07:30AM  The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal Benzinga
Oct-26-18 09:00AM  Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018 GlobeNewswire
Oct-24-18 01:11PM  China cutting rare earth output, unnerving global manufacturers Reuters -5.51%
Oct-16-18 09:15AM  Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-12-18 09:00AM  Why Adamas Pharmaceuticals, Inc. Stock Sank in September Motley Fool +5.03%
Oct-08-18 08:30AM  Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI in Parkinsons Disease Patients with Dyskinesia GlobeNewswire
Oct-05-18 05:51PM  Adamas Announces New Employment Inducement Grant GlobeNewswire -7.86%
01:59PM  When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)? Simply Wall St.
Oct-04-18 09:00AM  Adamas Announces Publication of Data Demonstrating Dyskinesias Impact on Activities of Daily Living in People with Parkinsons Disease GlobeNewswire
Sep-12-18 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Aug-20-18 08:25AM  Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies Discovering Underlying Factors of Influence GlobeNewswire
Aug-14-18 03:40PM  Edited Transcript of ADMS earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Aug-03-18 07:52AM  The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings Benzinga
Aug-02-18 07:05PM  Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:59PM  Adamas: 2Q Earnings Snapshot Associated Press
04:01PM  Adamas Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Adamas Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
Aug-01-18 09:00AM  Adamas Pharmaceuticals Launches Dyskinesia Is A Jerk, a Campaign to Raise Awareness and Highlight the Impact of Parkinsons Disease Dyskinesia GlobeNewswire
Jul-26-18 12:05PM  Adamas to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 2, 2018 GlobeNewswire
Jul-09-18 04:39PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Jun-25-18 07:10AM  Free Technical Research on Akorn and Three More Generic Drugs Equities ACCESSWIRE
Jun-22-18 09:12AM  Adamas Presents New Data Analysis Demonstrating that GOCOVRI Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day GlobeNewswire
Jun-08-18 05:55PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Jun-07-18 04:30PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
May-24-18 09:05AM  Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics GlobeNewswire
May-17-18 12:02PM  Edited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-09-18 04:05PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
May-04-18 08:16AM  Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down Benzinga
May-03-18 06:29PM  Adamas: 1Q Earnings Snapshot Associated Press
04:05PM  Adamas Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 03:22PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
Apr-26-18 04:05PM  Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018 GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinsons Disease Patients with Dyskinesia ACCESSWIRE
Apr-19-18 11:46AM  Adamas Pharmaceuticals Incs (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry? Simply Wall St. +7.04%
05:30AM  Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinsons Disease Patients with Dyskinesia GlobeNewswire
Apr-13-18 08:25AM  Analysis: Positioning to Benefit within Addus HomeCare, Adamas Pharmaceuticals, ManTech International, Yintech Investment, GRIDSUM HOLDING, and Blucora Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-12-18 05:09PM  Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting GlobeNewswire
Apr-03-18 09:00AM  Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment GlobeNewswire +5.90%
Mar-27-18 12:36PM  Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating Benzinga
10:00AM  Acorda Files Parkinson's Drug Marketing Application in EU Zacks
Mar-20-18 03:26PM  Edited Transcript of ADMS earnings conference call or presentation 22-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 09:00AM  Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinsons Disease Patients with Dyskinesia GlobeNewswire
Mar-14-18 08:25AM  Recent Analysis Shows SMART Global, DBV Technologies S.A, ICON, Adamas Pharmaceuticals, Shenandoah Telecommunications, and Costamare Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-12-18 02:06PM  What Should Investors Know About Adamas Pharmaceuticals Incs (NASDAQ:ADMS) Future? Simply Wall St.
09:51AM  Adamas stock rises 5% on strong launch of Parkinson's drug MarketWatch
09:08AM  Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals Zacks
Mar-06-18 02:35PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-26-18 04:59AM  New Strong Sell Stocks for February 26th Zacks
Feb-25-18 06:29PM  Adamas Pharmaceuticals (ADMS) Q4 2017 Earnings Conference Call Transcript Motley Fool
Feb-23-18 12:35PM  Here's Why Adamas Pharmaceuticals Dropped Today Motley Fool -5.07%
Feb-22-18 04:59PM  Adamas reports 4Q loss Associated Press
12:00PM  Adamas Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:07AM  Adamas Pharmaceuticals Earnings Preview Benzinga
Feb-20-18 02:21PM  Why Adamas Pharmaceuticals Fell Today Motley Fool -21.85%
10:07AM  3 Biotech Stocks To Avoid Forbes
Feb-19-18 08:01PM  Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER GlobeNewswire
Feb-13-18 04:01PM  Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018 GlobeNewswire
Feb-09-18 05:26PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Feb-08-18 09:00AM  Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice GlobeNewswire
Feb-07-18 02:09PM  Adamas to Present at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-01-18 04:05PM  Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal GlobeNewswire
Jan-29-18 08:30AM  Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-23-18 08:29PM  Adamas Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jan-22-18 05:50PM  Is Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Worth $38.19 Based On Its Intrinsic Value? Simply Wall St. +6.81%
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rhodes Jennifer JCBO, GC & Compliance OfficerMar 20Sale7.991,79214,31831,612Mar 21 04:39 PM
Went Gregory TChief Executive OfficerMar 20Sale7.996,31950,489176,291Mar 21 04:37 PM
MERRIWEATHER ALFRED GChief Financial OfficerMar 20Sale7.998576,84724,603Mar 21 04:47 PM
Patni RajivChief Medical OfficerMar 20Sale8.002,37418,99219,141Mar 21 04:45 PM
Prentiss Christopher BChief Accounting OfficerMar 20Sale8.001,1859,48029,541Mar 21 04:43 PM
Prentiss Christopher BChief Accounting OfficerDec 20Sale7.512281,71218,226Dec 26 05:09 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerDec 20Sale7.524253,19633,404Dec 21 04:47 PM
Went Gregory TChief Executive OfficerNov 07Buy12.983,85049,956199,242Nov 08 06:04 PM
MERRIWEATHER ALFRED GChief Financial OfficerSep 21Sale19.181,66531,93525,460Sep 21 07:12 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerJun 21Sale25.481,00225,53133,794Jun 22 04:50 PM
KING RICHARDChief Operating OfficerJun 21Sale25.482,50163,72548,856Jun 22 04:47 PM